Genentech Inc. Newsletter
-
Genentech $569M deal lifts Starpharma stock 73%
22 Sep 2025 23:58 GMT
… to Roche Holding AG subsidiary Genentech Inc. in a deal worth …
-
Australia's Starpharma announces collaboration worth $564 M with Genentech for cancer therapies
22 Sep 2025 15:36 GMT
… collaboration worth $564 M with Genentech for cancer therapies
September 22 … dendrimer-drug conjugates that incorporate Genentech medicines for certain oncology targets … . Starpharma has granted Genentech an exclusive worldwide license under …
-
Genentech to file for oral SERD approval on Phase III breast cancer win
22 Sep 2025 14:01 GMT
… data is currently immature, Genentech said there is a clear … safety signals were observed.
Genentech said its study marks … of the Roche group, Genentech CMO and global product … ER-positive breast cancer.”
Genentech’s giredestrant is an investigational …
-
Starpharma Announces a Collaboration and License Agreement with Genentech
22 Sep 2025 11:30 GMT
… dendrimer-drug conjugates that incorporate Genentech medicines for certain oncology … targets. Starpharma has granted Genentech an exclusive worldwide license under … proprietary dendrimer technology platform, DEP®. Genentech’s world-class scientific expertise …
-
Genentech launches 'population health' unit led by former head of DEI effort
19 Sep 2025 12:21 GMT
-
Genentech parent Roche adds weight to obesity-related portfolio with potential $3.5 billion deal
18 Sep 2025 19:39 GMT
-
Biogen’s high-dose Spinraza turned down by FDA due to CMC troubles
24 Sep 2025 17:14 GMT
… (onasemnogene abeparvovec) and Roche-owned Genentech’s small molecule Evrysdi (risdiplam …
-
<![CDATA[Hercessi, Biosimilar to Herceptin, Shows Favorable Efficacy, Safety in Treating HER2+ MBC in Real-World Setting ]]>
24 Sep 2025 18:10 GMT
… ), a biosimilar to trastuzumab (Herceptin; Genentech), demonstrated favorable efficacy and safety …
-
Glioblastoma Multiforme Market Set for Robust Growth with Breakthrough Therapies and Rising Research Investments 2025
24 Sep 2025 12:34 GMT
… the Glioblastoma Multiforme Market include:
Genentech USA, Inc.
Pfizer Inc.
Amgen …
-
Pharma’s next generation of blockbuster antibodies takes a ‘more is better’ approach
24 Sep 2025 12:27 GMT
… has already generated two blockbusters: Genentech’s Hemlibra, a hemophilia treatment …